Legal Cannabis Lacking Research: Why U.S. Must Prioritize Funding

As cannabis legalization surges across the United States, research into its health effects, consumer behavior, and public policy (PPHC ) implications continues to lag behind. The disconnect is not just frustrating—it’s dangerous. Without meaningful federal and state investment in cannabis research, we’re left navigating one of the most significant public health and social shifts in modern history with limited data and even fewer answers.

A 2025 paper published¹ in the Journal of Cannabis Research lays bare the scale of the problem and outlines a way forward. By analyzing the funding ecosystem at both federal and state levels, the authors identify critical gaps, systemic roadblocks, and opportunities for change. Their message is clear: without real investment, cannabis science can not meet the moment. And make no mistake—the moment is now.

The Numbers Tell the Story: Key Highlights of the Study

According to the study, titled “State funding for cannabis research: an analysis of funding mechanisms and levels,” cannabis legalization has not come with a proportional investment in science. States are profiting millions from cannabis taxes and fees, but most are failing to reinvest that revenue into research.

While 38 states have legalized cannabis for either medical or adult use, the study reveals that only 17 of those states have even established mechanisms. However, of the 17 states with legislative mechanisms for funding cannabis research:

• Only 12 have allocated funds.
• Six states delivered research money directly to academic institutions.
• Five states funneled money through state agencies.
• California used both models, showing flexibility in its research strategy.

Additionally, funding levels vary dramatically. For example:

• Florida allocated $1.5 million to its Consortium for Medical Marijuana Clinical Outcomes Research.
• Minnesota earmarked $2.5 million annually from cannabis tax revenue to fund a cannabis research center at the University of Minnesota.
• California leads the pack with a robust $10 million annual investment for ten years, supporting cannabis research across public universities.

On the other hand, many states that have legalized cannabis have failed to commit even a fraction of that money to scientific inquiry. This imbalance highlights a growing concern among scientists, policy makers, and public health professionals: we are moving fast on legalization, but we’re not keeping pace with understanding the plant’s full effects, benefits, and potential risks.

Why Cannabis Research Funding Matters

Cannabis is a complex plant with over 100 cannabinoids and other compounds, such as cannaflavins and terpenes. It has the potential to alleviate chronic pain, reduce inflammation, ease anxiety, and manage symptoms of serious conditions like epilepsy, cancer, or multiple sclerosis. However, it can also pose risks, particularly when it comes to adolescent use, mental health issues, or drug interactions.

Here’s what greater research funding could help achieve:

Improved Public Health Guidance

We need real, peer-reviewed data to guide consumers, medical professionals, and lawmakers. Without comprehensive research, cannabis users are left to navigate health decisions without scientifically backed advice.

Informed Policy Development

Policymakers need solid data to shape laws around potency limits, marketing, youth access, workplace safety, and more. Research can help governments create educated and effective regulations that protect the public while supporting industry growth.

Medical Advancements

Funding clinical trials could unlock cannabis’s potential as a treatment for PTSD, neurodegenerative diseases, and other critical health concerns.

Consumer Safety and Product Innovation

Research can help develop safer, more effective products, from edibles to topicals to high-CBD formulations. It also plays a key role in identifying contaminants, understanding dosage, and improving labeling standards.

Economic Impact

Investing in research could spark innovation in technology, agriculture, health care, and education—driving job creation and entrepreneurial opportunities.

Missed Opportunities and the Need for Action

Despite these potential benefits, most states remain reluctant to invest. This is a missed opportunity, especially when you consider that cannabis sales are projected to reach over $30 billion annually in the U.S. A small portion of that could fund groundbreaking research and benefit the entire population.

By not supporting research, states risk being reactive rather than proactive. They’re responding to issues, such as accidental ingestion by children or public confusion over THC potency, after they arise, rather than preventing them through informed policy and education.

So, what can be done? The paper offers a roadmap:

Stable Funding

States should earmark a fixed annual amount or dedicate a percentage of cannabis tax revenue to fund research. Fixed budgets offer predictability; percentage-based models grow with the industry.

Infrastructure Investment

Beyond grants, states must support institutions and researchers in building lasting infrastructure—from labs and data systems to regulatory partnerships.

Academic-State Collaboration

Some of the most successful models involve embedding researchers directly into policy processes, as seen in Colorado and California. These partnerships allow science to influence regulation in real time.

Access to Real-World Products

Federal and state reforms must prioritize giving researchers access to dispensary-grade cannabis products. Without that, studies cannot reflect what people are actually consuming.

Lack of research is not just a scientist’s problem. It affects everyone, from patients trying to manage chronic conditions to public health officials trying to prevent impaired driving. It leaves regulators guessing about how to label edibles, or how to define “impairment.” It makes it harder to design programs that protect youth while ensuring access for those who benefit medically.

Final Thoughts

For decades, the federal status of cannabis as a Schedule I drug has kept it shrouded in regulatory red tape, scientific ambiguity, and policy inertia. But as states move swiftly toward legalization, the science has struggled to keep up.

According to the National Institutes of Health (NIH), cannabis research received just $369 million in funding in 2021. For comparison, tobacco research received $598 million and alcohol research $568 million—despite cannabis’s rapidly expanding legal and consumer footprint.

This lack of research creates a dangerous blind spot. Without evidence, regulators are forced to make decisions on labeling, dosing, youth prevention, and public health strategy without the data they need. The same is true for clinicians looking to guide patients, or lawmakers weighing equity policies and criminal justice reforms.

The Journal of Cannabis Research paper is a wake-up call, one grounded in data and driven by urgency. The path forward is clear: fund the science, build the infrastructure, and make research part of the legalization blueprint. The cannabis industry and its consumers deserve regulations rooted in science, not speculation. It’s time to fund the future we are already living in.

Studies Referenced:

^{1. Balla, A., Boyle, R.G. & Dempsey, C. State funding for cannabis research: an analysis of funding mechanisms and levels. J Cannabis Res 7, 15 (2025). https://doi.org/10.1186/s42238-025-00264-0}